Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
Market
0.0%
Details
- Resolved Date
- 2/19/26
- Study Completion
- 3/1/26
- Company
- Traws Pharma, Inc.
- Ticker
- TRAW
- Type
- Trial Status
- Recruiting
- Trial Size
- 90
- Volume
- $0
- NCT
- NCT07157007
- Drug Description
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19. It will also learn about the safety of drug Ratutrelvir. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
This Phase 2 trial has already had a trial-specific public readout. Traws’ Feb. 19, 2026 release/8-K says the completed analysis confirmed a differentiated profile vs PAXLOVID, with fewer adverse events, no viral rebounds, equivalent symptom resolution, and management called the data meaningful and supportive of continued development.
Sources
ClinicalTrialsclinicaltrials.gov2/1/26
Study Details | NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
ClinicalTrials.gov identifies NCT07157007 as the Phase 2 early-stage trial of ratutrelvir in mild-to-moderate COVID-19 sponsored by Traws Pharma.
View source
Web Searchsec.gov2/19/26
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients
Company 8-K exhibit says completed Phase 2 results confirmed a differentiated profile versus PAXLOVID with fewer adverse events, no viral rebounds, and equivalent time to sustained symptom resolution; CMO said the data were meaningful and support continued evaluation.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
